<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dc3/6287667/17d53570f146/ott-11-8723Fig1.jpg"/> </div> <div class="text-side"> <h1>Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder.</h1> <p>Representative section of gallbladder mass biopsy.Notes: H&amp;E stained sections of gallbladder mass biopsy show sheets of neoplastic cell infiltration with focal necrosis (A and B, 4× and 10×, respectively). High magnification micrograph (H&amp;E staining, 40×) of gallbladder biopsy shows large neoplastic cells with abundant clear cytoplasm. (C) Immunohistochemistry staining demonstrates positivity of S100 (D), SOX-10 (E), and HMB45 (F).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30584330/" target="_blank">30584330</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>